Literature DB >> 8021681

Increased concentration of C4d complement protein in CSF in amyotrophic lateral sclerosis.

Y Tsuboi1, T Yamada.   

Abstract

Plasma and CSF concentrations of C4d and the circulating immune complex to C1q were measured in 27 patients with amyotrophic lateral sclerosis (ALS) or cervical spondylosis. There was no significant difference among groups in plasma C4d or in plasma or CSF concentrations of the circulating immune complex to C1q. The ALS group, however, had a significantly higher CSF concentration of C4d than the group with cervical spondylosis, as well as a higher C4d index (CSF to plasma C4d ratio x serum to CSF albumin ratio). These results suggest that augmented complement activation in the CNS occurs in ALS. Increased CSF concentration of C4d or raised C4d index may serve as a basis for differentiating ALS from cervical spondylosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8021681      PMCID: PMC1073037          DOI: 10.1136/jnnp.57.7.859

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  14 in total

1.  Experimental autoimmune motoneuron disease.

Authors:  J I Engelhardt; S H Appel; J M Killian
Journal:  Ann Neurol       Date:  1989-09       Impact factor: 10.422

2.  Complement-activated oligodendroglia: a new pathogenic entity identified by immunostaining with antibodies to human complement proteins C3d and C4d.

Authors:  T Yamada; H Akiyama; P L McGeer
Journal:  Neurosci Lett       Date:  1990-05-04       Impact factor: 3.046

3.  Deposits of IgG and C3 in the spinal cord and motor cortex of ALS patients.

Authors:  H Donnenfeld; R J Kascsak; H Bartfeld
Journal:  J Neuroimmunol       Date:  1984-02       Impact factor: 3.478

4.  Evidence for immune-complex formation in patients with amyotrophic lateral sclerosis.

Authors:  M B Oldstone; C B Wilson; L H Perrin; F H Norris
Journal:  Lancet       Date:  1976-07-24       Impact factor: 79.321

Review 5.  Amyotrophic lateral sclerosis: an unconventional autoimmune disease?

Authors:  D B Drachman; R W Kuncl
Journal:  Ann Neurol       Date:  1989-08       Impact factor: 10.422

6.  IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis.

Authors:  J I Engelhardt; S H Appel
Journal:  Arch Neurol       Date:  1990-11

7.  Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies.

Authors:  P Vanguri; C L Koski; B Silverman; M L Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

8.  Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis.

Authors:  J I Engelhardt; J Tajti; S H Appel
Journal:  Arch Neurol       Date:  1993-01

9.  Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue.

Authors:  T Kawamata; H Akiyama; T Yamada; P L McGeer
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

10.  Long-term neuromuscular dysfunction produced by passive transfer of amyotrophic lateral sclerosis immunoglobulins.

Authors:  O D Uchitel; F Scornik; D A Protti; C G Fumberg; V Alvarez; S H Appel
Journal:  Neurology       Date:  1992-11       Impact factor: 9.910

View more
  12 in total

Review 1.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

2.  C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice.

Authors:  Christian S Lobsiger; Severine Boillée; Christine Pozniak; Amir M Khan; Melissa McAlonis-Downes; Joseph W Lewcock; Don W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-29       Impact factor: 11.205

Review 3.  Let's make microglia great again in neurodegenerative disorders.

Authors:  Marie-Victoire Guillot-Sestier; Terrence Town
Journal:  J Neural Transm (Vienna)       Date:  2017-10-12       Impact factor: 3.575

Review 4.  Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.

Authors:  Christi Kolarcik; Robert Bowser
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

5.  Complement alterations in the CSF of patients with amyotrophic lateral sclerosis.

Authors:  P Annunziata
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-03       Impact factor: 10.154

Review 6.  CSF markers in amyotrophic lateral sclerosis.

Authors:  Joanna Tarasiuk; Alina Kułakowska; Wiesław Drozdowski; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2012-05-04       Impact factor: 3.575

Review 7.  Biomarkers in frontotemporal lobar degenerations--progress and challenges.

Authors:  William T Hu; John Q Trojanowski; Leslie M Shaw
Journal:  Prog Neurobiol       Date:  2011-04-30       Impact factor: 11.685

Review 8.  Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis.

Authors:  Franca Orsini; Daiana De Blasio; Rosalia Zangari; Elisa R Zanier; Maria-Grazia De Simoni
Journal:  Front Cell Neurosci       Date:  2014-11-07       Impact factor: 5.505

Review 9.  Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System.

Authors:  Sarah M Carpanini; Megan Torvell; Bryan Paul Morgan
Journal:  Front Immunol       Date:  2019-03-04       Impact factor: 7.561

10.  Evaluation of Peripheral Immune Activation in Amyotrophic Lateral Sclerosis.

Authors:  Mengli Wang; Zhen Liu; Juan Du; Yanchun Yuan; Bin Jiao; Xuewei Zhang; Xuan Hou; Lu Shen; Jifeng Guo; Hong Jiang; Kun Xia; Jianguang Tang; Ruxu Zhang; Beisha Tang; Junling Wang
Journal:  Front Neurol       Date:  2021-06-24       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.